The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The standard treatment approach for patients with stage III-IV DLBCL is combination
chemotherapy. Receipt of consolidation radiotherapy (RT) after effective chemotherapy was
associated with improved in-field control and event-free survival. However, it is uncertain
for the radiotherapy field size to treat for these patients after chemotherapy.
Involved-field radiotherapy (IFRT) after effective chemotherapy is a common strategy for
patients with stage III-IV DLBCL. There is not a clinical trial to research whether the
sequential narrowed radiotherapy field size (involved-site radiotherapy, ISRT) can obtain the
same efficacy as IFRT and decrease toxicities related to radiotherapy.